TABLE 2.

Tidal volume analysis.

Group	Week0	Week4	Week8	Week12	Week16	Week20
Control	1.71 ± 0.11	1.81 ± 0.17	1.86 ± 0.13	1.89 ± 0.11	1.93 ± 0.09	1.94 ± 0.07
COPD	1.80 ± 0.12	1.74 ± 0.14	1.70 ± 0.15**	1.65 ± 0.16**	1.62 ± 0.12**	1.58 ± 0.14**
BJF	1.75 ± 0.14	1.72 ± 0.13	1.69 ± 0.11	1.64 ± 0.15	1.69 ± 0.07	1.69 ± 0.11##
AICAR	1.74 ± 0.17	1.70 ± 0.14	1.68 ± 0.13	1.62 ± 0.15	1.59 ± 0.11Δ	1.61 ± 0.08Δ
BJF + AICAR	1.76 ± 0.09	1.72 ± 0.10	1.65 ± 0.08	1.64 ± 0.08	1.67 ± 0.10	1.69 ± 0.07##
APL	1.75 ± 0.15	1.71 ± 0.15	1.69 ± 0.17	1.62 ± 0.12	1.67 ± 0.09	1.66 ± 0.07#

Data are presented as mean ± SD (n = 6 per group). ^∗∗ P < 0.01, ^∗ P < 0.05 vs. control group;^## P < 0.01, ^# P < 0.05 vs. model group; ^ΔΔ P < 0.01, ^Δ P < 0.05 vs. BJF group; ^▲▲ P < 0.01, ^▲ P < 0.05 vs. 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) group; and ^□□ P < 0.01, ^□ P < 0.05 vs. BJF + AICAR group. APL, aminophylline.